

Relistor - (12mg/0.6ml; Solution, Subcutaneous)

| | | | |
|------------------------------|---|-----------------------------|---------------------|
| Generic Name | Methylnaltrexone bromide | Innovator | SALIX Pharma |
| Dosage | 12mg/0.6ml; Solution, Subcutaneous | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | Less Than 5 |
| Other ANDA developers | Less Than 5 | Tentative Approvals | Less Than 5 |
| Final Approvals | Less Than 5 | Generic Launches | None |
| Indication | Indicated for the treatment of opioid-induced constipation in patients with advanced illness who are receiving palliative care, when response to laxative therapy has been insufficient | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Relistor - (150 mg; Tablet, Oral)

| | | | |
|------------------------------|--|-----------------------------|---------------------|
| Generic Name | Methylnaltrexone bromide | Innovator | SALIX Pharma |
| Dosage | 150 mg; Tablet, Oral | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | Less Than 5 |
| Other ANDA developers | Less Than 5 | Tentative Approvals | Less Than 5 |
| Final Approvals | None | Generic Launches | None |
| Indication | Indications for RELISTOR: Opioid-induced constipation (OIC) in adults with chronic non-cancer pain, including chronic pain related to prior cancer or its treatment in patients who do not require frequent opioid dosage escalation | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Relistor - (8mg/ 0.4ml; Solution, Subcutaneous)

| | | | |
|------------------------------|--|-----------------------------|---------------------|
| Generic Name | Methylnaltrexone bromide | Innovator | SALIX Pharma |
| Dosage | 8mg/ 0.4ml; Solution, Subcutaneous | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | Less Than 5 |
| Other ANDA developers | Less Than 5 | Tentative Approvals | Less Than 5 |
| Final Approvals | Less Than 5 | Generic Launches | None |
| Indication | Indicated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, where response to laxative therapy has been insufficient | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.